FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2331844802> ?p ?o ?g. }

• W2331844802 endingPage "1472" @default.
• W2331844802 startingPage "1466" @default.
• W2331844802 abstract "In Brief Study Design. Regulation of nerve growth factor (NGF) by 2 different anti-inflammatory drugs was investigated in vitro using isolated human intervertebral disc (IVD) cells stimulated with the proinflammatory cytokine interleukin-1 (IL-1). Objective. To investigate the regulation of NGF by a synthetic steroid and a selective cyclooxygenase-2 (COX-2) inhibitor and to clarify the biological role of prostaglandin E2 (PGE2) in this process. Summary of Background Data. NGF is known to play an important role in pain, including low back pain, and to be induced by proinflammatory cytokines in IVD cells. However, the effect of clinically used drugs for managing low back pain on the regulation of NGF is unclear. Methods. Isolated human IVD cells were stimulated with interleukin-1 (IL-1) in the presence or absence of dexamethasone or a selective COX-2 inhibitor (NS-398). NGF expression and release were determined by real-time polymerase chain reaction and enzyme-linked immuno sorbent assay, respectively. Inhibition of PGE2 release was determined by enzyme-linked immuno sorbent assay. The effects of exogenous PGE2 and its receptor (E-series prostanoid receptors [EPs] 1–4) agonists were also tested for NGF regulation. Results. IL-1 transiently induced, in a dose-dependent manner, the induction of NGF in human IVD cells. Pretreatment with dexamethasone strongly inhibited the NGF expression, whereas NS-398 significantly enhanced it at the concentration at which PGE2 release was substantially inhibited. Exogenous PGE2 inhibited IL-1 induction of NGF and this effect was mimicked when EP2 and EP4, but not EP1 and EP3, agonists were supplemented to the culture. Conclusion. Although selective COX-2 inhibitors have been shown to be effective for acute low back pain by inhibiting PGE2 release, our findings suggest that it may have a limited efficacy because it exaggerated NGF expression, whereas dexamethasone inhibited it. On the other hand, PGE2 had an inhibitory function for NGF induction by mediating EP2/4 in human IVD cells. Further studies are needed to clarify whether these observations could take place in vivo. Level of Evidence: N/A Interleukin-1–induced nerve growth factor (NGF) expression in human intervertebral disc cells. Dexamethasone inhibited the NGF expression whereas NS-398 enhanced it. Exogenous prostaglandin E2 and its receptor agonists EP2/EP4, inhibited the NGF expression. These results suggest that cyclooxygenase-2 inhibition has a limited efficacy for low back pain treatment. Confirmatory in vivo studies are needed." @default.
• W2331844802 created "2016-06-24" @default.
• W2331844802 creator A5020180629 @default.
• W2331844802 creator A5047469054 @default.
• W2331844802 creator A5057947442 @default.
• W2331844802 creator A5065942042 @default.
• W2331844802 creator A5068724534 @default.
• W2331844802 creator A5071483582 @default.
• W2331844802 creator A5072325538 @default.
• W2331844802 creator A5084096323 @default.
• W2331844802 date "2013-08-01" @default.
• W2331844802 modified "2023-10-18" @default.
• W2331844802 title "Regulation of Nerve Growth Factor by Anti-Inflammatory Drugs, a Steroid, and a Selective Cyclooxygenase 2 Inhibitor in Human Intervertebral Disc Cells Stimulated With Interleukin-1" @default.
• W2331844802 cites W1480365149 @default.
• W2331844802 cites W1505597474 @default.
• W2331844802 cites W1574199527 @default.
• W2331844802 cites W1603520326 @default.
• W2331844802 cites W1664741673 @default.
• W2331844802 cites W1840804593 @default.
• W2331844802 cites W1964774089 @default.
• W2331844802 cites W1976415203 @default.
• W2331844802 cites W2003522028 @default.
• W2331844802 cites W2007473008 @default.
• W2331844802 cites W2020902418 @default.
• W2331844802 cites W2022235629 @default.
• W2331844802 cites W2025271102 @default.
• W2331844802 cites W2029706883 @default.
• W2331844802 cites W2039948531 @default.
• W2331844802 cites W2044474568 @default.
• W2331844802 cites W2052094743 @default.
• W2331844802 cites W2053425043 @default.
• W2331844802 cites W2056320231 @default.
• W2331844802 cites W2059519296 @default.
• W2331844802 cites W2063695629 @default.
• W2331844802 cites W2070256833 @default.
• W2331844802 cites W2071828798 @default.
• W2331844802 cites W2075143033 @default.
• W2331844802 cites W2080532845 @default.
• W2331844802 cites W2081939457 @default.
• W2331844802 cites W2083666514 @default.
• W2331844802 cites W2083960007 @default.
• W2331844802 cites W2087865533 @default.
• W2331844802 cites W2093622830 @default.
• W2331844802 cites W2111110611 @default.
• W2331844802 cites W2118436663 @default.
• W2331844802 cites W2119108332 @default.
• W2331844802 cites W2121787709 @default.
• W2331844802 cites W2125208830 @default.
• W2331844802 cites W2134318006 @default.
• W2331844802 cites W2136331722 @default.
• W2331844802 cites W2150271931 @default.
• W2331844802 cites W2151014103 @default.
• W2331844802 cites W2163756514 @default.
• W2331844802 cites W2167481223 @default.
• W2331844802 cites W2169198863 @default.
• W2331844802 cites W2241112928 @default.
• W2331844802 doi "https://doi.org/10.1097/brs.0b013e318294edb1" @default.
• W2331844802 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23574818" @default.
• W2331844802 hasPublicationYear "2013" @default.
• W2331844802 type Work @default.
• W2331844802 sameAs 2331844802 @default.
• W2331844802 citedByCount "22" @default.
• W2331844802 countsByYear W23318448022014 @default.
• W2331844802 countsByYear W23318448022015 @default.
• W2331844802 countsByYear W23318448022016 @default.
• W2331844802 countsByYear W23318448022017 @default.
• W2331844802 countsByYear W23318448022019 @default.
• W2331844802 countsByYear W23318448022020 @default.
• W2331844802 countsByYear W23318448022021 @default.
• W2331844802 countsByYear W23318448022022 @default.
• W2331844802 crossrefType "journal-article" @default.
• W2331844802 hasAuthorship W2331844802A5020180629 @default.
• W2331844802 hasAuthorship W2331844802A5047469054 @default.
• W2331844802 hasAuthorship W2331844802A5057947442 @default.
• W2331844802 hasAuthorship W2331844802A5065942042 @default.
• W2331844802 hasAuthorship W2331844802A5068724534 @default.
• W2331844802 hasAuthorship W2331844802A5071483582 @default.
• W2331844802 hasAuthorship W2331844802A5072325538 @default.
• W2331844802 hasAuthorship W2331844802A5084096323 @default.
• W2331844802 hasConcept C126322002 @default.
• W2331844802 hasConcept C134018914 @default.
• W2331844802 hasConcept C164027704 @default.
• W2331844802 hasConcept C170493617 @default.
• W2331844802 hasConcept C181199279 @default.
• W2331844802 hasConcept C185592680 @default.
• W2331844802 hasConcept C2776914184 @default.
• W2331844802 hasConcept C2777198256 @default.
• W2331844802 hasConcept C2777361909 @default.
• W2331844802 hasConcept C2777956040 @default.
• W2331844802 hasConcept C2778266237 @default.
• W2331844802 hasConcept C2778423431 @default.
• W2331844802 hasConcept C2778690821 @default.
• W2331844802 hasConcept C2779689624 @default.
• W2331844802 hasConcept C2780401358 @default.
• W2331844802 hasConcept C2780664492 @default.
• W2331844802 hasConcept C55493867 @default.
• W2331844802 hasConcept C71924100 @default.
• W2331844802 hasConcept C74172505 @default.

• next